We Are Leaders In Antibody and Peptide Discovery
Originally formed in 2008 to exploit the macrocyclic Cyclotide plant microprotein family as a therapeutic or delivery scaffold using phage display libraries.

Cyclogenix Technology expanded into:
  • Fully Human phage scFv antibody libraries
  • Large Cyclotide scaffold & VNAR single domain libraries
  • Filings on half-life extension IP, specific oral availability/BBB transfer sequences
Our current research focus:
  • Oral delivery (metabolic/cardiovascular)
  • BBB agent bioavailability (stroke/neurodegenerative)
  • Multispecifics (oncology)

 

The Team

Duncan McGregor (CEO)

More than 15 years experience in innovative protein engineering, and drug discovery display technologies e.g. invented CIS display at Isogenica. Previously at Scotgen Biopharm, RRS, Haptogen and Isogenica.

Bill Eldridge (CSO)

More than 15 years experience in the biotech industry. Previously at Pfizer, Cambridge Antibody Technology and Isogenica

Chris Ullman (Consultant)

More than 15 years experience in the biotech industry. Previously at Gendaq, Isogenica, currently consulting to Cyclogenix.

Simon Robins (Company Secretary)

With over 30 years of experience in diagnostics research.